-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside | Zendy

Nicolas Lepareur | Zendy; Valérie Ardisson | Zendy; Nicolas Noiret | Zendy; Étienne Garin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside

Author(s) -

Nicolas Lepareur,

Valérie Ardisson,

Nicolas Noiret,

Étienne Garin

Publication year - 2012

Publication title -

international journal of molecular imaging

Language(s) - English

Resource type - Journals

eISSN - 2090-1712

pISSN - 2090-1720

DOI - 10.1155/2012/278306

Subject(s) - lipiodol , medicine , hepatocellular carcinoma , radiation therapy , rhenium , medical physics , nuclear medicine , cancer research , oncology , surgery , inorganic chemistry , chemistry

Hepatocellular carcinoma (HCC) is the 5th most common tumour worldwide and has a dark prognosis. For nonoperable cases, metabolic radiotherapy with Lipiodol labelled with β -emitters is a promising therapeutic option. The Comprehensive Cancer Centre Eugène Marquis and the National Graduate School of Chemistry of Rennes (ENSCR) have jointly developed a stable and efficient labelling of Lipiodol with rhenium-188 (E β max = 2.1 MeV) for the treatment of HCC. The major “milestones” of this development, from the first syntheses to the recent first injection in man, are described.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research